产品目录
| 编号 | 化学名称 | Cas号 | 纯度 | 化学结构 |
|---|---|---|---|---|
| 611820 | mTOR-IN-1 | 1207358-59-5 | 98% |  |
| mTOR-IN-1 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 1.5 | ||||
| 161009023 | Miltefosine | 58066-85-6 | 98% by HPLC |  |
| Miltefosine targets cellular membranes, modulating cell membrane permeability, membra | ||||
| 169701 | 1-METHYL-5-NITRO-1H-INDOLE | 29906-67-0 | 98% by HNMR/HPLC |  |
| 1-METHYL-5-NITRO-1H-INDOLE CAS#29906-67-0 | ||||
| 16071022 | Mubritinib | 366017-09-6 | 98% by HPLC |  |
| Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under deve | ||||
| 16070814 | MK-8245 | 1030612-87-3 | 98% by HPLC |  |
| MK-8245 | ||||
| 16070813 | MLN120B | 783348-36-7 | 98% by HPLC |  |
| MLN120B | ||||
| 16070106 | MS417 | 916489-36-6 | 98% by HPLC |  |
| MS417, also known as GTPL7512, is a potent and selective BRD4 inhibitor. MS417 inhibi | ||||
| 16062901 | Molidustat (BAY85-3934) | 1154025-82-6 | 98% by HPLC | |
| Molidustat (BAY85-3934) | ||||
| 1662118 | MK-8931 ( Verubecestat ) | 1286770-55-5 | 98% by HPLC/HNMR | -cas-1286770-55-5.png) |
| MK-8931(verubecestat)是一种BACE抑制剂，是由默沙东公司研制开发。主 | ||||
| 16062101 | Methyl 2,5-dimethylnicotinate | 63820-72-4 | 98% by HPLC |  |
| Methyl 2,5-dimethylnicotinate | ||||
| 16060603 | MDK-5220 | 1796565-52-0 | 98% by HPLC |  |
| MDK-5220 exhibits an orexin agonist activity and is expected to be useful as an excel | ||||
| 032514 | MK-5172 | 1350514-68-9 | 98% |  |
| Coming soon! | ||||
| 030904 | Mirodenafil | 862189-95-5 | 98% |  |
| Coming soon! | ||||
| 030901 | MK-2866 | 1202044-20-9 | 98% |  |
| Coming soon! | ||||
| 030101 | MCC950 | 210826-40-7 | 98% |  |
| MCC950 is a potent, selective, small-molecule inhibitor of NLRP3 with IC50 of 7.5 nM | ||||
| 020106 | MRE-269 | 475085-57-5 | 98% |  |
| MRE-269 is a long-acting and highly selective prostacyclin receptor agonist. | ||||
| 011906 | MSX-122 | 897657-95-3 | 98% |  |
| MSX-122 is a n orally bioavailable inhibitor of CXCR4 with potential antineoplastic a | ||||
| 011902 | ME-143 | 852536-39-1 | 98% |  |
| ME -143 is a derivative of triphendiol and is a highly potent, pan acting ant-cancer. | ||||
| 011805 | MK-2206 | 1032349-93-1 | 98% |  |
| MK-2206 2Hcl is an orally bioavailable allosteric inhibitor of the serine/threonine p | ||||
| 011801 | MK-8033 | 1001917-37-8 | 98% |  |
| MK8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt | ||||
| 011301 | ML324 | 1222800-79-4 | 98% |  |
| ML324 is a potent JMJD2 demethylase inhibitor with demonstrated antiviral activity. | ||||
| 011110 | MK-1775 | 955365-80-7 | 98% |  |
| MK-1775 is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM; hinders G2 DNA | ||||
| 010806 | MK-2461 | 917879-39-1 | 98% |  |
| MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met. | ||||
| 010606 | Medetomidine hydrochloride | 86347-15-1 | 98% |  |
| Medetomidine Hydrochloride is an agonist of adrenergic alpha-2 receptor, which is use | ||||
| 010424 | MK-2048 | 870005-19-9 | 98% |  |
| MK-2048 is a second generation integrase inhibitor, intended to be used against HIV i | ||||
| 51627 | MK7622 | 1227923-29-6 | 98% by HPLC |  |
| MK-7622isused as adjunctive therapy to acetylcholinesterase inhibitors (AChEIs) for t | ||||
| 123007 | MK-4827 | 1038915-60-4 | 98% |  |
| MK-4827 is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM; with grea | ||||
| 122949 | MK-0752 | 471905-41-6 | 98% |  |
| MK-0752 is a moderately potent -secretase inhibitor, which reduces A40 production wit | ||||
| 122819 | MK8745 | 885325-71-3 | 98% |  |
| MK-8745 is a novel Aurora-A specific inhibitor. MK8745 induced apoptotic cell death i | ||||
| 122217 | MK 886 | 118414-82-7 | 98% |  |
| MK 886 is a leukotriene antagonist. It may perform this by blocking the 5-lipoxygenas | ||||